TTR amyloidosis is a progressive disease in which a protein called transthyretin misfolds and clumps into insoluble fibers that build up in organs, especially the heart and nerves. The protein is normally produced by the liver and carries thyroid hormone and vitamin A through the bloodstream. When it becomes unstable, it breaks apart and reassembles into harmful deposits called amyloid fibrils that gradually damage tissue. The condition comes in two forms and, until recently, had limited treatment options, but newer therapies are significantly extending survival.
How the Protein Breaks Down
Transthyretin normally circulates as a compact unit made of four identical protein pieces locked together (a tetramer). In TTR amyloidosis, that four-piece structure falls apart. The individual pieces then refold into sticky, sheet-like shapes that latch onto each other, forming progressively larger clumps: first small clusters, then long, rigid fibers. These fibers deposit in the spaces between cells in organs throughout the body, where they physically crowd out healthy tissue and trigger inflammation. The deposits are insoluble, meaning the body has no efficient way to clear them once they form.
Two Types With Different Causes
The hereditary form (hATTR) is caused by an inherited gene mutation that makes the transthyretin protein less stable than normal. Over 120 different mutations have been identified, and only one copy of the altered gene is needed to develop the disease, since it follows an autosomal dominant pattern. The most clinically significant mutation in the United States is called Val122Ile. It is carried by roughly 3.4% of Black Americans, translating to an estimated 1.5 million carriers nationwide. This variant predominantly causes heart problems and tends to progress faster than other forms.
Wild-type TTR amyloidosis (wtATTR) involves no genetic mutation at all. Instead, the normal protein becomes unstable with age and begins misfolding on its own. It typically affects people over 65 and overwhelmingly involves the heart. Because it develops slowly and mimics other conditions common in older adults, it has historically been underdiagnosed.
Heart Involvement
The heart is the organ most commonly and most dangerously affected. Amyloid fibrils infiltrate the heart muscle, causing the walls to thicken and stiffen. On imaging, the wall of the left ventricle often measures 12 mm or more, compared to a normal range of roughly 6 to 11 mm. This thickening doesn’t make the heart stronger. It makes it rigid, so it can’t relax properly between beats and struggles to fill with blood.
The result is heart failure with preserved ejection fraction, a type of heart failure where the heart still squeezes normally but can’t fill adequately. Symptoms include shortness of breath (especially with exertion or lying flat), swelling in the legs and ankles, fatigue, and exercise intolerance. Atrial fibrillation is also common. Interestingly, carpal tunnel syndrome often appears years before any heart symptoms and is now recognized as a potential early warning sign.
A recent international study screened older heart failure patients who had thickened heart walls but no prior amyloidosis diagnosis. Among those evaluated, 18% turned out to have TTR amyloid cardiomyopathy. Prevalence was even higher in certain groups: 24% of men versus 10% of women, and over 40% of patients aged 85 and older. These numbers suggest the disease is far more common than previously thought, particularly in elderly men with unexplained heart failure.
Nerve Involvement
Hereditary TTR amyloidosis frequently damages the peripheral nerves, producing a condition called polyneuropathy. It usually begins in the feet and hands with numbness, tingling, or burning pain, then gradually spreads upward and involves motor function, making it harder to walk or grip objects. The autonomic nervous system is also affected. This can cause drops in blood pressure when standing, chronic digestive problems like diarrhea or constipation, bladder dysfunction, and erectile dysfunction. Wild-type disease can cause mild nerve symptoms too, but the severe polyneuropathy pattern is much more characteristic of the hereditary form.
How It’s Diagnosed
Diagnosing TTR amyloidosis used to require a tissue biopsy, but a nuclear imaging scan has largely replaced that approach for the cardiac form. The scan uses a radioactive tracer that binds specifically to TTR amyloid deposits in the heart. In patients without a separate blood protein disorder called monoclonal gammopathy, the scan has a reported sensitivity of 99% and specificity of 86%, making it highly reliable as a non-invasive test. A blood test to rule out that protein disorder is done alongside the scan, and genetic testing then determines whether the disease is hereditary or wild-type.
Because the disease mimics other common conditions, diagnosis is often delayed. Someone might be treated for years for generic heart failure or peripheral neuropathy before amyloidosis is considered. Awareness of red flags, like unexplained heart wall thickening combined with a history of carpal tunnel syndrome or atrial fibrillation, has improved detection in recent years.
Treatment Approaches
Two distinct strategies now exist for treating TTR amyloidosis, and they work at different stages of the problem.
The first approach uses stabilizer drugs. These medications bind to the transthyretin tetramer and essentially hold the four protein pieces together, preventing them from falling apart into the misfolding-prone fragments that form amyloid. Tafamidis is the most established drug in this class. In clinical trials, patients who started tafamidis early had a median survival of roughly 67 months from treatment, compared to about 35 months in those who initially received a placebo before switching to the drug. That gap highlights how much early treatment matters.
The second approach uses gene silencer drugs. Rather than stabilizing the protein, these medications reduce how much transthyretin the liver produces in the first place, cutting levels by 80 to 90%. Vutrisiran is one such drug used for cardiac amyloidosis. By dramatically lowering the total supply of the protein, there is far less raw material available to misfold. This approach may hold particular advantages for hereditary disease, since stabilizers leave the mutant protein present (in a more stable form), while silencers eliminate most of it entirely.
Prognosis and the Impact of Early Detection
Without treatment, median survival from diagnosis is approximately 2.5 years for patients with the Val122Ile hereditary variant and about 3.6 years for wild-type disease. These numbers are sobering, but they reflect a period when diagnosis often came late and treatment options were limited.
Modern therapies have substantially changed the outlook. In the longest follow-up data available, patients who received continuous tafamidis treatment from the start survived nearly twice as long as those whose treatment was delayed. The consistent finding across studies is that earlier diagnosis and earlier treatment lead to meaningfully better outcomes. Once significant organ damage has occurred, it becomes much harder to reverse, so catching the disease before it progresses too far is the single most important factor in long-term survival.
For people with a family history of the disease, genetic testing can identify carriers before symptoms develop. Carriers can then be monitored so that treatment begins at the first sign of organ involvement rather than years into the disease.